Topadur Pharma AG
PrivateLast Round
Series C
Extension
Oct 1, 2024
Est. Valuation
$47.38M
Total Funding Raised
$25.75M
Company Overview
Topadur Pharma AG is a clinical-stage biopharmaceutical company that develops dual-acting small-molecule therapies to restore microcirculation and promote tissue regeneration for age-related diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Topadur Pharma AG Comparables
Compare Topadur Pharma AG with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aurealis Therapeutics | 79% | |
| ElkosRx, LLC | 78% | |
| Ilya Pharma | 73% |
Topadur Pharma AG Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Oct 1, 2024 | ||||
| Strategic | Jun 6, 2024 | ||||
| Grant | Jan 5, 2024 | ||||
| Grant | Dec 20, 2023 | ||||
| Grant | Jun 7, 2022 | ||||
Convertible Debt | Oct 1, 2020 |
Key People
Founding team and executive leadership
Topadur Pharma AG Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CTI Life Sciences Fund | Grant |
| Eurostars SME programme | Grant |
| Korea Institute for Advancement of Technology | Grant |
| Innosuisse | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 15, 2025
Grew 33% QoQ, from 12 to 16 employees.
- May 1, 2025
Monthly visitors grew 119% MoM.
Recent news
Latest coverage and updates
- is_developingOct 29, 2026
Topadur Pharma AG and DEBRA Research announce a collaboration to explore a treatment approach for dystrophic epidermolysis bullosa using clinical-stage TOP-N53 and selected DualTOP small molecules, with studies addressing impaired wound healing and fibrosis in Germany and Austria on Oct 29th '26.
Topadur Pharma AG Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Topadur Pharma AG's valuation, stock price, and market status.
Is Topadur Pharma AG a public or private company?
Topadur Pharma AG is a private company.
What is the current stock price of Topadur Pharma AG?
Topadur Pharma AG is a private company, so its shares have no public market price. Caplight tracks Topadur Pharma AG's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Topadur Pharma AG worth (valuation)?
Topadur Pharma AG's valuation is estimated at $47.4M based on funding round data.
Can I buy Topadur Pharma AG stock?
Topadur Pharma AG shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Topadur Pharma AG's last funding round?
Topadur Pharma AG's most recent funding round was Series C Extension on October 1, 2024.
Who are the main investors in Topadur Pharma AG?
Key investors in Topadur Pharma AG include CTI Life Sciences Fund, Eurostars SME programme, Korea Institute for Advancement of Technology, Innosuisse.
Will Topadur Pharma AG IPO soon?
No public IPO plans have been announced for Topadur Pharma AG.
How can I track Topadur Pharma AG secondary market activity?
Caplight tracks bids, offers, and trades in Topadur Pharma AG's shares on secondary markets.